Pegylated interferon plus ribavirin for chronic hepatitis C: The role of combination therapy today, tomorrow and in the future

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 2, 2006, Pages 157-174

  Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatitis C; Interferons; Ribavirin

Indexed keywords

ALBUMIN ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIPROTOZOAL AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTIVIRUS AGENT; CILUPREVIR; CONSENSUS INTERFERON; INTERFERON; ISIS 14803; MERIMEPODIB; NITAZOXANIDE; PARACETAMOL; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; RNA;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; ERADICATION THERAPY; FLU LIKE SYNDROME; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; THROMBOCYTE ANOMALY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33646834272     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
2. Palitzsch KD, Hottentrager B, Schlottmann K, Frick E, Holstege A, Scholmerich J et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 1999;11:1215-20.
3. Desenclos JC. [Epidemiology of hepatitis C]. Rev Prat 2000;50:1066-70. French.
4. Puro V, Petrosillo N, Ippolito G, Aloisi MS, Boumis E, Rava L. Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections. Am J Public Health 1995;85:1272-5.
5. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
6. Ferenci SE, Rezman I, Strauss R, Ferenci P. Natural history of plasma donors infected with hepatitis C during epidemic outbreaks occurring in plasmapharesis centers. Hepatology 2004;40 Suppl 1:170A.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
8. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al. A comparison of three Interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-62.
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
10. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
11. Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225-30.
12. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
13. Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006;130: 231-64.
14. Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based antiviral therapy. Aliment Pharmacol Ther 2006;23:507-11.
15. Swain MG, Lai M-Y, Shiffman ML et al. Sustained virological response (SVR) is durable after treatment with peginterferon alfa-2a (40KD) (PEGASYS) alone or in combination with ribavirin (COPEGUS): Results of an ongoing long-term follow-up study. Hepatology 2005;42 Suppl 1:646A.
16. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P et al. Impact of interferon alfa2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
17. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferon alfa2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
18. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333-42.
19. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
20. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8.
21. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marines G, Lai MY et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004;40:675-81.
22. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
23. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004;99:636-44.
24. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.
25. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81.
26. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-91.
27. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535-9.
28. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29: 1124-30.
29. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
31. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004;20:825-30.
32. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Ciappina V, Patruno S et al. Area-under-the-curve for peginterfer-on alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antivir Ther 2005;10:201-5.
33. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther 2004;9:491-7.
34. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003;10:271-6.
35. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
36. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
37. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
38. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8.
39. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
40. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
41. Swain M, Foster GR, Fried MW, Hadziyannis SJ, Heathcote EJ, Jensen D et al. Clustering of poor prognostic factors in patients with chronic hepatitis C. J Hepatol 2005;42 Suppl 2:222.
42. Jacobson I, Brown R, Freilich B, Afdahl N, Kwo P, Santoro J et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R Study, a US community based trial. Hepatology 2005;42 Suppl 1:749A.
43. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
44. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9.
45. Ferenci P. Second thoughts about secondary analyses. Dig Liver Dis 2005;37:805-7; author reply 8-9.
46. Ferenci P. Weight-based dosing of pegylated interfer-on-alpha in chronic hepatitis C: just a marketing 'gag'? Dig Liver Dis 2003;35:601-6.
47. Marcellin P, Roberts S, Alberti A et al. Impact of baseline hepatitis C virus (HCV) RNA and genotype on the efficacy of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in patients with compensated cirrhosis/bridging fibrosis. Hepatology 2005;42 Suppl 1:672A.
48. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62.
49. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004;126:1409-15.
50. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005;42:266-74.
51. Puoti C, Bellis L, Martellino F, Guarisco R, Dell' Unto O, Durola L et al. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. J Hepatol 2005;43: 534-5.
52. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-7.
53. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.
54. Shiffman M, Gibas A, Rasenack J, Soman A, Zeuzem S. Fasting triglyceride levels, before, during and after treatment with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (RBV, COPEGUS) in patients infected with HCV genotype 2 or 3: the ACCELERATE serum triglyceride substudy. Hepatology 2005;42 Suppl 1:678A.
55. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250-7.
56. Ferenci P, Fried MW, Shiftman ML, Smith CI, Marinos G, Goncales FL et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
57. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
58. Jensen D, Morgan T, Marcellin P et al. Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon (-2a (40KD)/Ribavirin Therapy. Hepatology 2006. In press.
59. Sanchez Tapias JM, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M et al. Sustained virological response after prolonged treatment with peginterferon alfa-2a (40kd) (PEGASYS) and ribavirin (COPEGUS) in treatment-naive patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: Tera ViC-4 study. J Hepatol 2004;40 Suppl 1:150.
60. Ferenci P, Bischof M, Stauber R et al. Is shorter treatment with peginterferon alfa-2a (40KD) (PEGASYS(r)) plus ribavirin (COPEGUS(r)) possible in HCV genotype 1 'super-responders'? Preliminary results of a prospective randomized clinical trial. Hepatology 2005;42 Suppl 1:218A.
61. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
62. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
63. Ferenci P, Brunner H, Laferl H et al. Interim analysis of a randomized, controlled study comparing the efficacy of 40KD Peg-interferon alfa 2a in combination with 800mg or 400 mg ribavirin/day in chronic hepatitis C, Genotype 2/3. Gastroenterology 2005;Suppl.
64. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with Interferon nonresponsive chronic hepatitis C. Hepatology 2000;32:630-4.
65. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004;41:462-73.
66. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkonsky HL, Shiffman ML et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25;472-92.
67. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-23; discussion 947.
68. Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J et al. Sustained virologic response (SVR) in the EPIC3 Trial: Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005;42 Suppl 2:40.
69. Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Therneau T. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of "RENEW". Hepatology 2005;42 Suppl 1:219A.
70. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17:899-904.
71. Marcellin P, Freilich B, Andreone P, Brandao-Mello C, Di Bisceglie AM, Rai R et al. Interim safety analysis of patients enrolled in the randomized, international REtreatment with PEGASYS in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy (REPEAT) study. Hepatology 2005;42 Suppl1:657A.
72. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24.
73. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005;100:2338-54.
74. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
75. Lissen E, Clumeck N, Sola R, Mendes-Correa M, Montaner J, Nelson M et al. Histological response to peginterferon alfa-2a (40KD) (PEGASYS(r)) plus ribavirin (COPEGUS(r)) in patients with HIV-HCV coinfection: results of the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). Hepatology 2004;40 Suppl 1:241A.
76. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A et al; ANRS HCO2 RIBAVIC Study Team. Pegylated Interferon alfa-2b vs standard Interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
77. Dieterich DT, investigators A. HIV-HIV co-infected patients achieving a sustained virological response (SVR) with peginterferon alfa-2a (40 KD) (PEGASYS(r)) plus ribavirin (COPEGUS(r)) have improved health related quality of life (HRQL). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, October 30 - November 2, Washington, DC.
78. Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005;49:3997-4008.
79. Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during Interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005;40:47-52.
80. Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005;41:1806-9.
81. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. Aids 2004;18: F21-5.
82. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41:289-98.
83. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV et al. A randomized study comparing ribavirin and Interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-7.
84. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C et al. Interferon-alpha 2b plus ribavirin in patients with chrome hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-50.
85. Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-9.
86. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, Fernandez Ruiz M, Jimenez Garrido M, Lucena de la Poza JL et al. Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant Proc 2005;37:1482-3.
87. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004;41:462-73
88. Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006;44:275-82.
89. Romark-Laboratories. Romark to develop Alinia(r) (nitazoxanide) as new treatment for chronic hepatitis C 24-week data from international phase II study demonstrates virologic response to oral monotherapy. Press release. January 10, 2006. http://www.romark.com/index.php/media_center/press_releases/35.html
90. Bain V, Kaita K, Yoshida EM, Swain MG, Heathcote J, McHutchison J et al. A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albufer-On(TM) in IFN-alpha naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2005;42 Suppl 2:9.
91. Nelson D, Rustgi V, Balan V, McHutchsion J, Davis G, Lambiase L et al. A phase 2 study of albuferon in combination with ribavirin in non-responders to prior interferon therapy for chronic hepatitis C. Hepatology 2005;42 Suppl 1:278A.
92. Gorbakov W, Kim H, Oronsky B, Lang W. HCV RNA results from a phase II, randomized, open-label study of Omega interferon (IFN) with or without ribavirin in IFN-naive genotype 1 chronic HCV patients. Hepatology 2005;42 Suppl 1:705A.
93. Aora S, Xu C, Teng A, Yeh LT, Gish R, Lau D et al. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol 2005;45:275-85.
94. Wu JZ, Larson G, Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 2004;48:4006-8.
95. McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC Jr et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther 2005;10:635-43.
96. Gish RG, Nelson D, Arora S, Fried MW, Reddy KR, Xu Y et al. Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. J Hepatol 2005;42 Suppl 2:39.
97. Malcolm BA, Arassappan A, Bennett F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus (HCV) NS3 protease suppresses polyprotein maturation and enhances the antiviral activity of interferon-a-2b (IFN). Hepatology 2005;42 Suppl 1:535A.
98. Malcolm BA, Zeuzem S, Gupta S, Laughlin M, Zhang J. Modeling of hepatitis C viral dynamics during combination therapy with peginterferon alfa-2b (PEG-Intron) and the NS3 protease inhibitor SCH 503034. Hepatology 2005;42 Suppl 1:697A.
99. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (Peg-IFN-a). Hepatology 2005;42 Suppl 1:233A.
100. Chu H-M, Herrmann E, Reesink H et al. Pharmacokinetics of VX-950, and its effect on hepatitis C viral dynamics. Hepatology 2005;42 Suppl 1:694A.
101. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, vanVliet A, deRooij JV et al. Final results of a phase Ib, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 2005;42 Suppl 1:234A.
102. O'Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pappas S, Pockros P et al. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs retreatment with peg-interferon plus ribavirin (PegIFN/RBV) in hepatitis C patients with previous non-response to pegIFN/RBV: first interim results. Hepatology 2005;42 Suppl 1:234A.
103. Soler M, McHutchison JG, Kwoh TQ, Dorr FA, Pawlotsky JM. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (1RES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 2004;9:953-68.
104. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006;44:88-96.
105. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55.
106. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005;41:832-5.
107. Pawlotsky JM. Hepatitis C: it's a long way to new therapy, it's a long way to go. Gastroenterology 2004; 127:1629-32.